Cannabis and Its Potential Protective Role Against Inflammatory Bowel Disease: A Scoping Review.

Autor:	Nso N; Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, USA., Nyabera A; Internal Medicine, New York City Health and Hospitals/Queens, New York, USA., Nassar M; Internal Medicine, Icahn School of Medicine at Mount Sinai, New York City Health and Hospitals/Queens, New York, USA., Alshamam MS; Internal Medicine, Icahn School of Medicine at Mount Sinai, New York City Health and Hospitals/Queens, New York, USA., Sumbly V; Internal Medicine, Icahn School of Medicine at Mount Sinai, New York City Health and Hospitals/Queens, New York, USA., Vest M; Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, USA., Patel N; Internal Medicine, Chicago Medical School, Chicago, USA., Ojong G; Internal Medicine, La Magna Health/United Regional Hospital, Atlanta, USA., Rizzo V; Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2021 Oct 17; Vol. 13 (10), pp. e18841. Date of Electronic Publication: 2021 Oct 17 (Print Publication: 2021).
DOI:	10.7759/cureus.18841
Abstrakt:	Globally, around 15%-40% of patients suffering from inflammatory bowel disease (IBD) use Cannabis for pain reduction, increased appetite, and reduced need for other medications. Although many patients report having benefited by using Cannabis in IBD, there is still a lack of consensus regarding the use of Cannabis in IBD. The aim is to identify, explore and map literature on the potential protective role of Cannabis against IBD through this scoping review. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed during the search to answer the focal question: (1) Does Cannabis play a protective role against IBD as assessed by clinical remission; (2) If yes, what is the mechanism of action for this protective role. There were only three randomized controlled trials (RCTs) and three observational studies that satisfied the selection criteria of this scoping review. Although promising results including the improvement in general well-being/ Harvey-Bradshaw Index, health perception enhancement [4.1±1.43 to 7±1.42 (p = 0.0002)], weight gain, Crohn's Disease Activity Index (CDAI) score<150, Mayo scores (4-10), and reduction in clinical complications have been found in some studies, its medical use in IBD is still questionable due to the lack of high-quality evidence. Future RCTs studies should determine the cannabis treatment parameters and validate its safety and effectiveness in the IBD setting. The highlights include: the current literature provides inconclusive evidence concerning the protective role of cannabis for IBD patients; limited research evidence regarding the therapeutic use of cannabinoids for IBD warrants future investigation via RCTs; cannabis provides some benefits to IBD patients by improving their general well-being perceptions, Harvey-Bradshaw Index, Mayo scores, and minimizing their clinical complications. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Nso et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu